Recent progress in the drug development for CFTR corrector and modifiers with the potential to rescue CFTR function in CF patients may correct the pHi-regulatory dysfunction and reduce cancer risk (Phuan et al., 2019; Egan, 2020). Here, CFTR is linked to cystic fibrosis.